Medical weight management is one of the most talked-about areas of UK healthcare, but there is a lot of confusion about who actually qualifies for it. Eligibility is not a matter of simply wanting to lose weight, nor is it something you can decide for yourself online. It rests on a clinical framework built around your body mass index, your other health conditions and a careful check for reasons a medicine might not be safe for you. This article explains how that framework works and what a UK-registered clinician looks at before treatment is offered.
What medical weight management means in the UK
“Medical” weight management means weight loss supported by a healthcare professional, rather than diet and exercise attempted alone. In UK practice it usually combines structured lifestyle change with, in some cases, a prescription medicine. The important word is combines: medication is never intended to replace diet, activity and behavioural support. It is offered alongside them, and continued support is expected to run in parallel with any treatment.
This matters because the medicines used in weight management — principally the GLP-1 receptor agonists — work best when the underlying habits around eating, movement and sleep are being addressed at the same time. A clinician is assessing whether the whole package is appropriate for you, not just whether a number on a chart has been crossed.
It is also worth separating medical weight management from the over-the-counter and lifestyle products marketed for weight loss. Medical treatment involves prescription-only medicines, a clinical assessment before they are started, and ongoing review to check how you are responding and tolerating them. That structure is part of what makes it “medical” — there is a clinician accountable for the decision at every stage, and treatment can be adjusted or stopped if it is not right for you.
BMI thresholds used in NICE guidance
Body mass index (BMI) is the starting point. It is a rough measure of weight relative to height, and while it is imperfect, it gives clinicians a consistent way to gauge who may benefit from more intensive support. NICE, the body that guides NHS treatment in England and Wales, sets out BMI thresholds above which pharmacological weight management can be considered. Broadly, treatment is considered at higher BMI levels — commonly a BMI of 30 and above — with a lower threshold applied when weight is already affecting health.
Medicines you may have read about, such as Wegovy (semaglutide) and Mounjaro (tirzepatide), each have their own licensed criteria that a prescriber must follow. Crossing a BMI threshold does not mean a medicine is automatically suitable — it simply means the conversation about medical weight management can begin. Your clinician will advise based on your individual circumstances, including your ethnicity, since lower BMI cut-offs may be applied for some groups where health risk rises at a lower BMI.
BMI has well-recognised limitations, which is why clinicians do not read it in a vacuum. Because it does not distinguish muscle from fat, it can misclassify very muscular people, and it says nothing about where weight is carried. For that reason waist circumference is often used alongside BMI, since fat carried around the middle carries more metabolic risk. A clinician can interpret these measures together and in the context of your health, which is something a number on its own cannot do.
Comorbidities that change those thresholds
The BMI figure is rarely read in isolation. Weight-related health conditions, often called comorbidities, can shift the picture and are one of the main reasons a lower BMI threshold is applied. Conditions such as type 2 diabetes, high blood pressure (hypertension), obstructive sleep apnoea, and raised cholesterol all increase the health risk associated with excess weight, and their presence can make earlier intervention appropriate.
The list does not stop there. Prediabetes, non-alcoholic fatty liver disease, polycystic ovary syndrome, and the joint and mobility problems that excess weight can aggravate are all part of the wider picture a clinician considers. Obstructive sleep apnoea is a good example of why this matters: it is strongly linked to excess weight, disrupts sleep and daytime function, and carries cardiovascular risk of its own, so it can meaningfully change how urgently intervention is worth considering.
The logic throughout is that treatment decisions are about overall health risk, not weight for its own sake. Someone with type 2 diabetes and a BMI in the high-20s may be assessed differently from someone at the same BMI with no other conditions. This is precisely the kind of nuanced judgement that cannot be made from a blog or a self-assessment tool — it needs a clinician who can weigh your full history, current medicines and personal risk factors together.
Who is not suitable for these medications
Just as important as who qualifies is who should not take these medicines. Some situations are recognised contraindications — reasons a medicine should be avoided — and the BNF, the UK reference for prescribers, lists them clearly. Pregnancy and breastfeeding are among them: GLP-1 medicines are not used when you are pregnant, trying to conceive or breastfeeding. A personal or family history of medullary thyroid carcinoma, or the genetic condition multiple endocrine neoplasia type 2 (MEN2), is another recognised reason these medicines are not prescribed.
Other factors call for caution rather than an outright bar. A history of pancreatitis, certain gastrointestinal conditions, gallbladder disease, severe kidney problems, or other medicines you take may all influence the decision. Where you have diabetes and already take medicines that lower blood glucose, the combination needs careful review to reduce the risk of your blood sugar dropping too low. A clinician will also explore any history of an eating disorder, since that changes how — and whether — weight treatment should be approached.
None of this is something to work out alone. It is exactly why suitability is established through a consultation, where a clinician can ask the right questions and flag anything that means treatment is not right for you at this time. What counts as a firm barrier and what counts as a manageable caution is a clinical judgement, and it can change over time as your circumstances change.
What a clinician will assess during a consultation
A weight-management consultation is a structured clinical assessment, not a formality. Your clinician will typically confirm your height and weight to calculate BMI, ask about weight-related conditions, review your full medical history and current medications, and check for any of the contraindications and cautions above. They will also want to understand what you have already tried, your goals, and whether you are ready to combine medication with the lifestyle and behavioural support that any UK weight programme is built around.
Assessment does not end when a prescription is issued. If treatment is started, your clinician will usually plan follow-up to check how you are responding, how you are tolerating the medicine, and whether the dose or the plan needs adjusting. This ongoing review is a core part of doing weight management safely, and it is another reason the process is best handled through a clinical relationship rather than a one-off transaction.
From there, the clinician decides whether treatment may be considered for you and, if so, which option fits your circumstances. Eligibility is genuinely a clinical decision — it is not something the patient or a website determines. If you would like to understand your own eligibility, the most reliable next step is a consultation. You can also read more across our Weight Management guides to prepare for that conversation.